Janux therapeutics appoints shahram salek-ardakani, ph.d., chief scientific officer

San diego--(business wire)--janux therapeutics, inc. (nasdaq: janx) (janux), a biopharmaceutical company developing novel t cell engager immunotherapies, today announced the appointment of shahram salek-ardakani, ph.d., as chief scientific officer. dr. salek-ardakani will lead the scientific advancement of janux's proprietary tumor activated t cell engager (tractr) platform technology to expand janux's pipeline of next-generation t cell engager immunotherapies. dr. salek-ardakani joins janux fr
JANX Ratings Summary
JANX Quant Ranking